The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

ReNeuron taps Oxford Biomedica executive Catherine Isted as CFO

Fri, 06th Aug 2021 10:55

(Alliance News) - ReNeuron Group PLC on Friday said it has hired Catherine Isted, a finance professional and chartered accountant, as chief financial officer.

Bridgend, Wales-based ReNeuron is a biotechnology company focused on the development of novel stem cell therapies.

ReNeuron noted that Isted has 23 years of experience in the healthcare industry, including 12 years as a partner in two leading healthcare banking teams. She replaces Michael Hunt, who resigned in March after 20 years at the company

Isted "has an excellent knowledge of the healthcare sector and is highly skilled in equity capital markets, [mergers and acquisitions] and strategic business development," said Chair Ian Ross.

Isted joins ReNeuron from cell and gene therapy firm Oxford Biomedica PLC, where she was a member of the finance leadership team heading up Corporate Development and Investor Relations.

Formerly, Isted held research analyst and equity sales positions in the healthcare teams at New York-based investment bank Morgan Stanley, Dutch lender ABN AMRO Bank NV, Tokyo-based financial services provider Nomura Holdings Inc, and London-based stockbroker and investment bank Peel Hunt LLP.

Shares in ReNeuron were trading up 9.4% at 109.00 pence each in London on Friday morning. Oxford BioMedica shares were down 1.5% at 1,352.97p.

By Scarlett Butler; scarlettbutler@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.